PDF(Pubmed)
Abstract：
Head and neck squamous cell carcinoma (HNSCC) contribute to a significant global cancer burden. Developments in current therapeutic approaches have improved patient outcomes but have limited efficacy in patients with unresectable and/or recurrent HNSCC. RM-1929 near-infrared photoimmunotherapy (NIR-PIT) is an emerging treatment that is currently being investigated in a Phase III clinical trial and has been conditionally approved for the treatment of unresectable and/or recurrent HNSCC in Japan. Here, we collect a series of case reports and clinical trial data to assess the efficacy of RM-1929 NIR-PIT. Disease control rates ranged from 66.7 to 100% across these studies, and overall response rates ranged from 43.3 to 100%, suggesting positive clinical outcomes. Low-grade postoperative localized pain and edema were the most frequently reported side effects, and preliminary reports on quality of life and pain levels suggest that RM-1929 NIR-PIT does not significantly decrease quality of life and is manageable with existing pain management strategies, including opioids. These preliminary data in real-world use of RM-1929 NIR-PIT show that it is a well-tolerated therapy that has clinically meaningful outcomes for patients with unresectable and/or recurrent HNSCC.
摘要：
头颈部鳞状细胞癌（HNSCC）导致了巨大的全球癌症负担。当前治疗方法的发展改善了患者的预后，但在不可切除和/或复发性HNSCC的患者中疗效有限。RM-1929近红外光免疫疗法（NIR-PIT）是一种新兴的治疗方法，目前正在III期临床试验中进行研究，并已在日本有条件地批准用于治疗不可切除和/或复发性HNSCC。这里,我们收集了一系列病例报告和临床试验数据,以评估RM-1929NIR-PIT的疗效.在这些研究中，疾病控制率从66.7%到100%不等。总体反应率从43.3％到100％，提示积极的临床结果。低度术后局部疼痛和水肿是最常见的副作用。关于生活质量和疼痛水平的初步报告表明，RM-1929NIR-PIT不会显着降低生活质量，并且可以通过现有的疼痛管理策略来管理。包括阿片类药物。在现实世界中使用RM-1929NIR-PIT的这些初步数据表明，它是一种耐受性良好的治疗方法，对于不可切除和/或复发性HNSCC患者具有临床意义的结果。
